AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

LABCORP HOLDINGS INC. Director's Dealing 2018

Apr 5, 2018

30237_dirs_2018-04-05_77faeb1c-0509-4d5d-99a8-21de4762147b.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: LABORATORY CORP OF AMERICA HOLDINGS (LH)
CIK: 0000920148
Period of Report: 2018-04-03

Reporting Person: Ratliff John D (CEO, Covance Drug Development)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-04-03	Restricted Stock Unit	$	A	12120	Acquired		Common Stock (12120)	Direct

Footnotes

F1: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

F2: The Restricted Stock Units will vest in three installments as follows: 20% of the Restricted Stock Units will vest on April 3, 2019; 30% of the Restricted Stock Units will vest on April 3, 2020; and 50% of the Restricted Stock Units will vest on April 3, 2021.

F3: This number reflects the aggregate number of Restricted Stock Units held by the reporting person.